Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials

References

• Trevisani F, Di Marco F, Floris M, et al. Renal function outcomes in metastatic non-small-cell lung carcinoma patients treated with chemotherapy or immune checkpoint inhibitors: an unexpected scenario. Vaccines (Basel). 2022;10(5):679. Epub ahead of print 1 May doi: 10.3390/vaccines10050679.
   PubMed Web of Science ®Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. Epub ahead of print 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Herrmann SM, Sise ME. Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management. Kidney Med. 2021;3(6):1074–1081. doi: 10.1016/j.xkme.2021.08.008.
   PubMedGoogle Scholar
• Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-An overview. Rheumatol (United Kingdom). 2019;58(Supplement_7):vii7–vii16. doi: 10.1093/rheumatology/kez418.
   PubMedGoogle Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. doi: 10.1038/s41571-022-00600-w.
   PubMed Web of Science ®Google Scholar
• Moturi K, Sharma H, Hashemi-Sadraei N. Nephrotoxicity in the age of immune checkpoint inhibitors: mechanisms, diagnosis, and management. Int J Mol Sci. 2024;25:1–13. doi: 10.3390/ijms25010414.
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Epub ahead of print 29 March doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• NIH/NCI. Common terminology criteria for adverse events. NCI; 2017.
   Google Scholar
• Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
   Web of Science ®Google Scholar
• Higgins JPT, Savović J, Page MJ, et al. Chapter 8: assessing risk of bias in a randomized trial Cochrane. in: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, editors. Cochrane handbook for systematic reviews of interventions. Version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org/handbook/. Date accessed: January 22, 2023.
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced Squamous-Cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi: 10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi: 10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent Squamous-Cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi: 10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi: 10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-Line atezolizumab plus chemotherapy in Extensive-Stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi: 10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi: 10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (Danube): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574–1588. doi: 10.1016/S1470-2045(20)30541-6.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   PubMed Web of Science ®Google Scholar
• Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi: 10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–937.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi: 10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi: 10.1016/S1470-2045(16)30498-3.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi: 10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Gupta S, Portales-Castillo I, Daher A, et al. Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis. 2021;28(5):402–414.e1. doi: 10.1053/j.ackd.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Liu F, Wang Z, Li X, et al. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. Cancer Commun. 2023;43:214–224.
   Web of Science ®Google Scholar
• Menke J, Lucas JA, Zeller GC, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007;179(11):7466–7477. doi: 10.4049/jimmunol.179.11.7466.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi: 10.1016/j.ctrv.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-Related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020;22(4):39. Epub ahead of print 1 April doi: 10.1007/s11912-020-0897-9.
   PubMed Web of Science ®Google Scholar
• Delfino VDA. Nefrite Intersticial Aguda. In: condutas em nefrologia clínica e diálise - 1aEdição Como eu faço?, https://internacional.manole.com.br/condutas-em-nefrologia-clinica-e-dialise-1-edicao-como-eu-faco/p?gclid=CjwKCAjwrJ-hBhB7EiwAuyBVXTF24DMzJ1h69C0ap1mx5T_GPe4UOE1zhjQC7rSUGtKwGiUAWhVRnhoC4JkQAvD_BwE. 2022, accessed 1 April 2023).
   Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50. doi: 10.1136/annrheumdis-2016-209595.
   PubMed Web of Science ®Google Scholar
• Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatol (United Kingdom). 2019;58(Supplement_7):vii17–vii28. doi: 10.1093/rheumatology/kez465.
   PubMedGoogle Scholar
• Casals J, Acosta Y, Caballero G, et al. Differentiating acute interstitial nephritis From immune checkpoint inhibitors From other causes. Kidney Int Reports. 2023;8:672–675.
   PubMed Web of Science ®Google Scholar
• Xu LY, Zhao HY, Yu XJ, et al. Clinicopathological features of kidney injury related to immune checkpoint inhibitors: a systematic review. J Clin Med. 2023;12:1–14.
   Web of Science ®Google Scholar
• Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. Epub ahead of print doi: 10.1136/jitc-2021-002435.
   PubMed Web of Science ®Google Scholar
• Moss EM, Perazella MA. The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. Front Med. 2022;9:7–10. doi: 10.3389/fmed.2022.964335.
   Web of Science ®Google Scholar
• Cho S, Kang E, Kim JE, et al. Clinical significance of acute kidney injury in lung cancer patients. Cancer Res Treat. 2021;53(4):1015–1023. doi: 10.4143/crt.2020.1010.
   PubMed Web of Science ®Google Scholar
• Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease: systematic review and meta-analysis. Minerva Urol Nephrol. 2021;73(4):462–470. Epub ahead of print 26 March doi: 10.23736/S2724-6051.21.04116-3.
   PubMedGoogle Scholar
• Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5):611–616. doi: 10.1007/s40620-016-0309-2.
   PubMed Web of Science ®Google Scholar
• Li H, Xu J, Bai Y, et al. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Invest New Drugs. 2021;39(3):860–870. doi: 10.1007/s10637-020-01039-5.
   PubMed Web of Science ®Google Scholar
• Kitchlu A, Jhaveri KD, Wadhwani S, et al. A systematic review of immune checkpoint inhibitor–associated glomerular disease. Kidney Int Reports. 2021;6:66–77.
   PubMed Web of Science ®Google Scholar